Frontlight ResearchEarly access
Taking people in NetherlandsPhase 4
Keeping letrozole or changing to gonadotropins to help women with PCOS ovulate
Compares keeping letrozole or changing to gonadotropins in women with PCOS.
Key facts
- Who runs it
- Amsterdam UMC Stichting
- Where
- 'S-Hertogenbosch, AD Arnhem, Alkmaar, Almere, Amsterdam, Breda, Deventer, Dordrecht, Ede Gld, Eindhoven, Elsendorp, Emmen, Geleen, Gouda, Groningen, Heerenveen, Helmond, Hengelo Ov, Hilversum, Hoorn Nh, Nieuwegein, Nijmegen, Roermond, Rotterdam, Tilburg, Utrecht, and Veldhoven, NetherlandsSee the 33 sites
- Trial code
- Registry title
- Continuing ovulation induction with letrozole versus switching to gonadotropins in women with polycystic ovary syndrome (MOVIN-II study)
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 816 people, planned
- Started
- 1 Aug 2025
- Expected to end
- 1 Jun 2030
- Type of study
- Interventional
- Record updated
- 4 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with PCOS who wish to have a child, alone or as a couple. They must have ovulated for six cycles on letrozole.
- Age
- 18-42 years in the criteria (the record lists 18 to 64 Years overall).
- Sex
- Women only.
- Disease stage
- Diagnosed PCOS: no regular ovulation with high male hormones (acne, hair loss, extra hair growth, or blood tests), or polycystic ovaries on ultrasound.
- Earlier treatment
- Must have ovulated for six cycles on letrozole treatment.
- Biomarker or test result
- High male hormones shown by symptoms or by raised blood levels of total, bioavailable or free testosterone or dehydroepiandrosterone sulfate, or polycystic ovaries on ultrasound.
Main reasons for not taking part
- A reason you cannot take letrozole, including allergy to it, pregnancy or breastfeeding.
- Partner's total motile sperm count (VCM) under 3 million.
- Known blocked or diseased fallopian tubes on both sides (one open tube is allowed).
- Serious illness, such as poorly controlled type I or type II diabetes, liver disease or kidney disease.
- Unable to give informed consent.
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Couples or single women with childwish
- Diagnosed PCOS (normogonadotropic anovulation with hyperandrogenaemia (diagnosed clinically by the presence of excessive acne, androgenic alopecia, or hirsutism or by elevated serum levels of total, bioavailable, or free testosterone or dehydroepiandrosterone sulfate) or polycystic ovaries on ultrasound)
- Age 18-42 years
- Ovulatory for six cycles on letrozole treatment
Who cannot take part
- Additional contra-indications reported in the SPC are: Hypersensitivity to the active substance, during pregnancy and breast feeding
- Total motile sperm count (VCM) < 3 million
- Major medical morbidity (e.g. poorly controlled Type I or Type II diabetes, known liver disease or dysfunction based on serum liver enzyme testing, renal disease or abnormal serum renal function)
- Contra-indication to letrozole
- Known bilateral fallopian tube pathology or occlusion (patients with at least one patent fallopian tube are eligible)
- Inability to give informed consent
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Netherlands
- Jeroen Bosch Ziekenhuis Stichting'S-Hertogenbosch, NetherlandsTaking people
- Rijnstate Ziekenhuis StichtingAD Arnhem, NetherlandsTaking people
- Noordwest Ziekenhuisgroep StichtingAlkmaar, NetherlandsTaking people
- Flevoziekenhuis StichtingAlmere, NetherlandsTaking people
- Amsterdam UMC StichtingAmsterdam, NetherlandsTaking people
- Stichting OLVGAmsterdam, NetherlandsTaking people
- Amphia HospitalBreda, NetherlandsTaking people
- Deventer ZiekenhuisDeventer, NetherlandsTaking people
- Albert Schweitzer ZiekenhuisDordrecht, NetherlandsTaking people
- Ziekenhuis Gelderse Vallei StichtingEde Gld, NetherlandsTaking people
- Catharina Ziekenhuis StichtingEindhoven, NetherlandsTaking people
- Nij Geertgen Centrum voor vruchtbaarheid B.V.Elsendorp, NetherlandsTaking people
- Treant Ziekenhuiszorg StichtingEmmen, NetherlandsTaking people
- Zuyderland Medisch Centrum StichtingGeleen, NetherlandsTaking people
- Groene Hart ZiekenhuisGouda, NetherlandsTaking people
- Universitair Medisch Centrum GroningenGroningen, NetherlandsTaking people
- Frisius MCHeerenveen, NetherlandsTaking people
- Elkerliek ziekenhuisHelmond, NetherlandsTaking people
- Fertiliteitskliniek Twente B.V.Hengelo Ov, NetherlandsTaking people
- TergooiziekenhuizenHilversum, NetherlandsTaking people
- Dijklander ZiekenhuisHoorn Nh, NetherlandsTaking people
- Sint Antonius Ziekenhuis StichtingNieuwegein, NetherlandsTaking people
- Canisius Wilhelmina ZiekenhuisNijmegen, NetherlandsTaking people
- Radboud universitair medisch centrum StichtingNijmegen, NetherlandsTaking people
- Laurentius Ziekenhuis RoermondRoermond, NetherlandsTaking people
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsTaking people
- Ikazia ZiekenhuisRotterdam, NetherlandsTaking people
- Maasstad Ziekenhuis StichtingRotterdam, NetherlandsTaking people
- Sint Franciscus Vlietland Groep StichtingRotterdam, NetherlandsTaking people
- ETZ ElisabethTilburg, NetherlandsTaking people
- Diakonessenhuis StichtingUtrecht, NetherlandsTaking people
- Universitair Medisch Centrum UtrechtUtrecht, NetherlandsTaking people
- Maxima Medisch CentrumVeldhoven, NetherlandsTaking people
About the trial
What the trial wants to find out
To determine the clinical efficacy of continuing ovulation induction with letrozole versus switching to ovarian stimulation with gonadotropins, in terms of cumulative live birth rate improvement
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Continuing ovulation induction with letrozole versus switching to gonadotropins in women with polycystic ovary syndrome (MOVIN-II study)
- Plain-language title
- Keeping letrozole or changing to gonadotropins to help women with PCOS ovulateGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from 2024-519354-36-00, who can take part
- Record updated
- 4 September 2026